In recent years, innovation in the medical and health industry has been emerging and developing into one of the most active industries, 36Kr has witnessed and accompanied the growth of innovative enterprises in this field and brought professional voices to the industry.
To this end, 36Kr has launched the column "Medical and Health Industry Weekly", which will be released regularly in the future, providing readers with industry information from multiple perspectives such as capital, policy, finance, and new products.
On January 7, please check the weekly report of the medical and health industry. This weekly report includes the financing news reported by the "36Kr Venture Capital Channel" in the medical and health field last week.
Financing investments
- Elite Technology, a leading domestic liquid chromatography platform, received the first round of financing of more than 100 million yuan
Suzhou Elite Technology Co., Ltd. recently completed the first round of financing of over 100 million yuan, which was jointly led by Jifeng Capital and Suzhou Gaoxin Rongsheng, followed by Guofa Venture Capital, Qiaojing Capital, Lianxin Capital, LabTech, Qishi Dingfeng, etc., and Qifeng Capital served as the exclusive financial advisor. With more than 30 years of experience in the field of liquid chromatography instruments and related chromatography consumables, Elite Technology is a leading enterprise with independent research and development capabilities and mass production of products in China.
- Nureng Jie Biotech completed tens of millions of yuan in pre-A round of financing
Newbridge Biomedical Technology (Suzhou) Co., Ltd. announced that it will complete tens of millions of yuan in Pre-A round of financing in December 2023. This round of financing was led by Shanghai Science and Technology Venture Capital Co., Ltd., followed by Wuhan Baiying, Shanghai Sinan Park, Shanghai Biomedical Public Technology Service Co., Ltd. and other institutions, and the founding shareholders of Newbridge Biologics (including the core team) also made strategic additional investments. This round of financing will be used to further accelerate the company's R&D progress and team building. In situ transdifferentiation is a new generation of cell reprogramming technology iteratively developed on the Nobel Prize-winning iPSC technology, which is an important milestone breakthrough in the field of regenerative medicine. Nurenta Biologics is a biotechnology company that aims to develop novel gene therapy drugs using its proprietary proprietary cell in situ transdifferentiation technology.
- Hannuo Medical received more than 100 million yuan in Series E investment
Shenzhen Hannuo Medical Technology Co., Ltd. received more than 100 million yuan in Series E investment, which was led by Guangdong Traditional Chinese Medicine Health Fund managed by China Development Bank Capital and Guangdong Hengjian Holdings, followed by Zhejiang Development Asset Management Co., Ltd., Huashi Capital and other institutions, which is a new round of financing after Hannuo Medical completed hundreds of millions of yuan in Series D financing in early 2023. Hannuo Medical is making every effort to promote the development of the whole industry chain and the whole service chain of acute and critical care extracorporeal life support, starting from acute and critical cardiopulmonary support, cooperating with global leading enterprises and high-level hospitals to expand the market and application scenarios, and build a comprehensive and multi-organ extracorporeal life support product matrix.
- Likai Technology completed hundreds of millions of yuan in Series C financing
Shanghai Likai Technology Co., Ltd. successfully completed hundreds of millions of yuan in Series C financing. This round of financing was led by Guoxin Investment, followed by Tin Venture Capital and Heli Fund. In recent years, when investment has become more and more cautious, Likai Technology has continued to gain the favor of capital, and the company completed more than 200 million yuan in Series B+ financing in March 2022 and hundreds of millions of yuan in August 2021. The company is committed to taking neurointervention as the entry point, and through the strong two-wheel drive of "internal independent research and development capabilities + external BD exploration capabilities in the world", as well as a perfect closed-loop system of "R&D-product-marketing", it has become a leading innovative technology and service platform for global cerebrovascular disease devices and even the entire medical device industry.
- Full-Life announced the closing of a $63.3 million funding round
Full-Life Technology Co., Ltd., an international radiopharmaceutical treatment company, announced that it has closed a $63.3 million financing round, including a $47.3 million Series B equity financing and a $16 million credit facility. The financing will help the Company fast-track the development of its radiopharmaceutical pipeline and the development of drug manufacturing capabilities, as well as optimize its proprietary discovery platform, UniRDC™. With the completion of this financing, Full-Life has raised more than US$110 million since its inception in August 2021, including equity financing, debt financing and government subsidies.
- Dapu Biotech completed the B1 round of financing of 100 million yuan
Dapu Biotechnology Co., Ltd. announced that it has completed the B1 round of financing of 100 million yuan, which is led by Luxin Venture Capital, followed by Humble Investment, Guangzhou Financial Holding Fund, Daohe Technology Investment and Shenzhen Chenmuyun Technology. The financing funds will be used for the global commercialization of a number of droplet microfluidic platforms independently developed by Dapu Biosciences to create the world's leading life science instrument and tool platform. Founded in 2018 at the Hong Kong University of Science and Technology, Dapu Biotech is committed to providing the world's leading life science tools and is a leading droplet microfluidic company in China. The company has R&D and production centers in Shenzhen and Jiaxing, with a R&D team of nearly 100 people, focusing on the application of droplet microfluidic technology to the field of biomedicine and precision medicine, and is committed to becoming a complete solution provider integrating the R&D and production of microfluidic chips, instruments and reagents.
- Completed the first phase of the A round of financing of tens of millions of yuan
Guangzhou Weishi Optoelectronics Medical Technology Co., Ltd. announced the completion of the first phase of the A round of financing of tens of millions of yuan, which was exclusively invested by Green River Investment, with Lingshan Capital as the exclusive financial advisor. This round of financing will be mainly used to strengthen investment in technology research and development, expand production workshops to increase production capacity, further consolidate process, technology and supply capacity, and expand the company's leading edge in the core supply chain of electronic endoscopy. Founded in March 2019, Weishi Optoelectronics focuses on the R&D and production of core components and components such as medical electronic endoscope camera modules and medical electronic endoscope semi-finished products, provides R&D and OEM services (CDMO) for medical image processing machines and finished electronic endoscope products, provides packaging and testing services for medical ultra-miniature temperature and pressure sensors, and is a national high-tech enterprise, a specialized and special new small and medium-sized enterprise in Guangdong Province, and an innovative small and medium-sized enterprise in Guangdong Province.
- Weikaier Pharmaceutical completed more than 450 million yuan in Series C financing
Jiangsu Weikaier Pharmaceutical Technology Co., Ltd. announced the completion of more than 450 million yuan in Series C financing, which was jointly invested by China Life Equity, Deyi Capital, Hongyao Science and Technology, old shareholders Nanjing Innovation Investment Group and Hangzhou Huadian Investment. The funds will be mainly used to accelerate the advancement of the innovative drug R&D pipeline and the sustainable development of CROs/CDMOs across the entire drug industry chain. Weikaier Pharmaceutical is committed to the research and development of innovative drugs, the transfer of generic drug technology, the production and sales of pharmaceutical intermediates, and the provision of pharmaceutical services, clinical services, pharmaceutical intermediates process services, etc. Focusing on the unmet clinical needs in the fields of cardiovascular and cerebrovascular, tumor, endocrine and other diseases, the company has developed new cardiovascular and cerebrovascular drug Vicagrelor, new anti-tumor drug VC004, and highly selective JAK1 inhibitor VC005.
- Bingjing Intelligent completed tens of millions of yuan in Pre-A+ round of financing
Suzhou Bingjing Intelligent Medical Technology Co., Ltd. recently announced that it has completed tens of millions of yuan in Pre-A+ round of financing, which is jointly invested by Daotong Investment and Zhongxin Capital. The funds raised will be used to accelerate the research and development, clinical trials and marketing of the company's HD-ICE (next-generation high-definition high-speed intracardiac ultrasound), 3D-ICE, 4D-ICE and other products. Previously, Bingjing Intelligence completed the Pre-A round of financing led by Daotong Investment in July 2023. Founded in October 2021, focusing on cardiovascular interventional imaging, Bingjing Intelligence is a company that designs, develops and produces special digital interventional imaging products for heart and vascular diseases based on acoustic foundation, imaging as a means and digital medical revolution as the direction, and is committed to promoting the development of digital cardiovascular interventional imaging and empowering the whole scene and process of diagnosis and treatment of cardiovascular diseases with digitalization.
海外 New Things
- Overseas New Things | Apollo Therapeutics has raised $33.5 million in Series C2 funding to build a drug discovery platform in partnership with five top universities
Apollo Therapeutics is a UK-based combination biopharmaceutical company focused on translating basic medical research into medicines through a hub-and-spoke approach.
On January 2, the company announced that it had closed the second settlement of its Series C funding round, raising an additional $33.5 million, bringing the company's total Series C funding to $260 million. The Series C round was led by Patient Square Capital, with participation from a number of new investors, including M&G plc and two of the largest public pension plans in the United States, as well as existing investors such as Rock Springs Capital. Proceeds from the round will be used to advance the clinical development of the pipeline and further fund Apollo's drug discovery and development activities based on breakthroughs in basic medical research by partner institutions, as well as to license or acquire other clinical-stage projects that meet stringent screening criteria. "We are advancing a broad and diverse pipeline of more than 20 unrelated therapeutic programs, with multiple assets set to enter the clinic in early 2024," said Dr. Richard Mason, chief executive officer of Apollo Therapeutics......
- 海外 New Things | CardioMech获1300万美元融资，研发二尖瓣弦膜修复技术
CardioMech is a medical device company based in Minnesota, Norway, that develops transoral and transvalvular mitral valve chord repair technologies.
On January 2, CardioMech announced that it had raised $13 million in new funding for a total of $42 million in the round, with participation from both new and existing investors, including an undisclosed strategic investor. The company intends to use the funds to expand its business and R&D divisions. Rick Nehm, President of CardioMech, said: "I am excited to build on our long-standing and successful partnership with existing investors to develop this technology, and I am excited to work with new individual investors who truly believe in this team and this technology. Together, we will dramatically improve the standard of care for millions of patients with degenerative mitral regurgitation......
- Overseas New Things | BioCentriq raised $29.2 million in funding to provide CDMO services to cell therapy companies
BioCentriq is a global cell therapy contract development and manufacturing organization (CDMO) based in New Jersey, USA, dedicated to accelerating advances in cell and gene therapy.
On January 3, BioCentriq announced that it had raised $29.2 million in Series A funding, with undisclosed backers. BioCentriq plans to use the funding proceeds to further accelerate its innovation capabilities to provide end-to-end solutions for the development and manufacturing of cell therapies. The funds will also be used for strategic deployments to strengthen the company's R&D facilities, invest in advanced technologies, and expand its team of experts to meet the growing demand for scalable cell therapy solutions. This financing round marks a significant milestone in BioCentriq's mission to accelerate the delivery of innovative cell therapies by translating, optimizing, and scaling GMP manufacturing processes......
- 海外 New Things | ImmunityBio获3.2亿美元融资，研发针对癌症和传染病的新疗法
ImmunityBio is a clinical-stage immunotherapy company headquartered in California, USA, focused on developing next-generation therapeutics to drive immunogenic mechanisms for the treatment of cancer and infectious diseases.
On January 2, ImmunityBio announced that Oberland Capital will provide it with up to $320 million in royalty financing and equity investment, with $210 million in gross proceeds due on December 29, 2023. This additional funding provides the company with significant financial resources to accelerate its commercialisation progress, with antiquity to regulatory approvals and expansion of its pipeline in the broader urological cancer space. The proceeds will also be used to fund ongoing business operations and clinical trials to expand the indication of N-803 to multiple solid tumors......
- 海外 New Things | Radionetics Oncology获5250万美元A轮融资，研发针对癌症的放射性药物
Radionetics Oncology is a clinical-stage radiopharmaceutical company headquartered in California, USA, focused on developing novel drugs for the treatment of a variety of oncology indications.
On January 2, the company announced the completion of a $52.5 million Series A funding round. The round was led by Frazier Life Sciences, 5AM Ventures and new investor DCVC Bio, with participation from Crinetics Pharmaceuticals and GordonMD Global Investments, bringing the total funding round to $82.5 million. Radionetics plans to use the proceeds to advance its pipeline of potent small molecule radiopharmaceuticals targeting novel G protein-coupled receptors (GPCRs) for the treatment of adrenocortical cancer, breast, lung and other cancers. In conjunction with the financing, Radionetics Oncology also announced the appointment of Paul Grayson as its Chief Executive Officer......
Editor: Hai Ruojing
![Rockets teamed up with the Bulls!VanVleet was puzzled, Shin Kyung was lost, and LaVine was defeated by Udoka[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)